Literature DB >> 15602338

Nursing telephonic case management and pregnancy outcomes of mothers and infants.

Marianne H Hutti1, Wayne M Usui.   

Abstract

Limited success has been achieved in identifying high-risk pregnant women via prenatal risk identification tools. The purposes of this study were to examine a risk assessment and nursing telephonic case management protocol used to identify high-risk mothers and infants, and to evaluate the costs and benefits of the protocol. This study involved a retrospective review of insurance data held by a large managed care organization (MCO). Analyzed data included information about current and past medical problems, and current lifestyle risk factors. Data analysis included frequencies, chi2, t tests, and logistic regression analysis. Pregnant MCO members experienced fewer high-risk conditions versus nonmembers. The overall pregnancy cost for a member was 1,818 dollars versus 4,587 dollars for a nonmember. Members experienced 2.5 times fewer babies hospitalized in the NICU, and significantly fewer mothers with high-risk conditions. The MCO program reduces costs and promotes better maternal and infant outcomes.

Entities:  

Mesh:

Year:  2004        PMID: 15602338     DOI: 10.1097/00129234-200411000-00008

Source DB:  PubMed          Journal:  Lippincotts Case Manag        ISSN: 1529-7764


  2 in total

1.  Exploring Implementation of m-Health Monitoring in Postpartum Women with Hypertension.

Authors:  Sarah J Rhoads; Christina I Serrano; Christian E Lynch; Songthip T Ounpraseuth; C Heath Gauss; Nalin Payakachat; Curtis L Lowery; Hari Eswaran
Journal:  Telemed J E Health       Date:  2017-05-05       Impact factor: 3.536

2.  Impact of a telenursing service on satisfaction and health outcomes of children with inflammatory rheumatic diseases and their families: a crossover randomized trial study protocol.

Authors:  Anne-Sylvie Ramelet; Béatrice Fonjallaz; Joachim Rapin; Christophe Gueniat; Michaël Hofer
Journal:  BMC Pediatr       Date:  2014-06-18       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.